サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1760532

ファブリー病の世界市場レポート 2025年

Fabry Disease Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.89円
ファブリー病の世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ファブリー病市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.0％で31億米ドルに成長します。予測期間における成長の原動力は、新生児スクリーニングプログラムの拡大、希少疾患治療に対する規制当局の支援、より広範なヘルスケアアクセス、遠隔医療と遠隔診療の台頭、個別化医療に対する需要の高まりにあるとみられます。この期間の主な動向には、酵素補充療法の採用、遺伝子検査の進歩、早期発見のためのAIとデジタルツールの統合、AIを活用した診断アルゴリズム、遺伝子治療の進展などがあります。

個別化医療が重視されるようになったことで、ファブリー病市場の今後の成長が見込まれます。個別化医療は、個人の遺伝的体質、環境、ライフスタイルに基づいて治療を調整し、治療成果を向上させる。このアプローチは、特定の患者のニーズに合わせて治療をカスタマイズすることで、治療効果を高め、副作用を軽減します。個別化医療は、患者固有の遺伝子変異と疾患の重症度を考慮した治療計画の開発を可能にし、その結果、治療成績が向上し、副作用が減少します。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者向けに新たに承認した個別化治療は16件で、2022年の6件から大幅に増加したと指摘しました。その結果、個別化医療が重視されるようになったことが、ファブリー病市場の拡大を促す重要な要因となっています。

ファブリー病市場の主要企業は、PEG化酵素補充療法（ERT）などの革新的な治療に注力し、治療成績の向上、患者のアドヒアランスの強化、従来のERTに関連する免疫系反応の軽減を図っています。PEG化ERTは標準的なERTを改良したもので、酵素にポリエチレングリコール（PEG）を添加して安定性を向上させ、体内での投与期間を延長し、免疫反応を最小限に抑えます。例えば、2023年5月、Chiesiグループに属するChiesi Global Rare Diseases社は、米国食品医薬品局（FDA）が成人ファブリー病患者の治療薬としてPRX-102（pegunigalsidase alfa）を承認したと発表しました。この承認は、140名以上の患者を含む包括的な臨床プログラムと最長7.5年の長期追跡調査によって裏付けられたもので、本療法が良好な安全性プロファイルとともに、腎臓のGb3沈着物の減少および腎機能の維持に有効であることが実証されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のファブリー病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のファブリー病市場：成長率分析
  • 世界のファブリー病市場の実績：規模と成長、2019年～2024年
  • 世界のファブリー病市場の予測：規模と成長、2024年～2029年、2034年
  • 世界のファブリー病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のファブリー病市場：タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • タイプ1
  • タイプ2
  • その他のタイプ
  • 世界のファブリー病市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 酵素補充療法
  • 口腔療法
  • 補助療法
  • その他の治療法
  • 世界のファブリー病市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 血液検査
  • 遺伝子検査
  • 非経口検査
  • その他の診断
  • 世界のファブリー病市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界のファブリー病市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院
  • ホームケア
  • 専門クリニック
  • その他のエンドユーザー
  • 世界のファブリー病市場、タイプ1のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • クラシックファブリー病
  • 後発性ファブリー病
  • 世界のファブリー病市場、タイプ2のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 心臓血管系に焦点を当てたファブリー病
  • 腎臓に焦点を当てたファブリー病
  • 世界のファブリー病市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • バリアントファブリー病
  • Xリンクされたファブリー病

第7章 地域別・国別分析

  • 世界のファブリー病市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界のファブリー病市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ファブリー病市場：競合情勢
  • ファブリー病市場：企業プロファイル
    • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • JCR Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Sumitomo Pharma Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Chiesi Farmaceutici S.p.A.
  • Amicus Therapeutics Inc.
  • Idorsia Pharmaceuticals Ltd
  • Sangamo Therapeutics Inc.
  • uniQure N.V.
  • Protalix BioTherapeutics Inc.
  • Spur Therapeutics Inc.
  • Exegenesis Bio Inc.
  • ISU ABXIS Co. Ltd.
  • Eleva GmbH
  • AceLink Therapeutics Inc.
  • 4D Molecular Therapeutics Inc.
  • iBio Inc.
  • Freeline Therapeutics Holdings plc
  • Greenovation Biotech GmbH

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ファブリー病市場2029年：新たな機会を提供する国
  • ファブリー病市場2029年：新たな機会を提供するセグメント
  • ファブリー病市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35409

Fabry disease is an uncommon genetic condition resulting from a shortage of the enzyme alpha-galactosidase A, which causes fat to accumulate in the cells and organs of the body. Treatment aims to alleviate symptoms, prevent further organ damage, and enhance the quality of life for those affected.

Fabry disease has several forms, including types 1, 2, and others. Type 1 Fabry disease, a rare genetic disorder that typically starts in childhood, is caused by a near-total absence of the alpha-galactosidase A enzyme, leading to the accumulation of fat in cells and organs. Treatment options include enzyme replacement therapy, oral medications, adjunct therapies, and additional methods. Diagnosis is achieved through various techniques, including blood tests, genetic testing, parenteral tests, and other diagnostic approaches. Distribution channels for treatment include hospital pharmacies, online pharmacies, and retail pharmacies, serving different end users such as hospitals, homecare providers, specialty clinics, and other healthcare facilities.

The fabry disease market research report is one of a series of new reports from The Business Research Company that provides fabry disease market statistics, including the fabry disease industry global market size, regional shares, competitors with the fabry disease market share, detailed fabry disease market segments, market trends, and opportunities, and any further data you may need to thrive in the fabry disease industry. This fabry disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fabry disease market size has grown strongly in recent years. It will grow from $2.10 billion in 2024 to $2.28 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth observed in the historical period can be credited to factors such as heightened awareness and diagnosis of rare diseases, the development of specialized healthcare infrastructure, government incentives and orphan drug designations, increased funding for rare disease research, and the initial introduction of therapies.

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period is expected to be driven by the expansion of newborn screening programs, regulatory support for orphan and rare disease treatments, broader healthcare access, the rise of telemedicine and remote care, and a growing demand for personalized medicine. Key trends during this period include the adoption of enzyme replacement therapy, advancements in genetic testing, the integration of AI and digital tools for early detection, AI-powered diagnostic algorithms, and progress in gene therapy.

The increasing emphasis on personalized medicine is anticipated to drive the growth of the Fabry disease market in the future. Personalized medicine tailors treatments based on an individual's genetic makeup, environment, and lifestyle, which improves treatment outcomes. This approach enhances treatment effectiveness and reduces side effects by customizing therapies to meet specific patient needs. Personalized medicine enables the development of treatment plans that consider a patient's unique genetic mutation and disease severity, resulting in better outcomes and fewer adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit, noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from six approvals in 2022. As a result, the growing emphasis on personalized medicine is a key factor driving the expansion of the Fabry disease market.

Major companies in the Fabry disease market are focusing on innovative therapies, such as PEGylated enzyme replacement therapy (ERT), to improve treatment outcomes, enhance patient adherence, and reduce immune system reactions linked to traditional ERT. PEGylated ERT is a modified version of standard ERT, where polyethylene glycol (PEG) is added to the enzyme to improve stability, extend its duration in the body, and minimize immune responses. For example, in May 2023, Chiesi Global Rare Diseases, part of the Chiesi Group, announced that the U.S. Food and Drug Administration (FDA) approved PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval was supported by a comprehensive clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy's effectiveness in reducing kidney Gb3 deposits and maintaining kidney function, with a favorable safety profile.

In June 2022, Kyorin, a Japan-based pharmaceutical company, acquired a license from CellGenTech to develop and commercialize a treatment for Fabry disease. With this acquisition, Kyorin intends to leverage CellGenTech's genetically modified human adipocytes (GMAC) technology to create a new treatment for Fabry disease. CellGenTech Inc. is a biotechnology company from Japan that specializes in ex vivo gene therapy solutions for rare diseases, including Fabry disease.

Major players in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH.

North America was the largest region in the fabry disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in fabry disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the fabry disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fabry Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fabry disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fabry disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fabry disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Type 1; Type 2; Other Types
  • 2) By Treatment: Enzyme Replacement Therapy; Oral Therapy; Adjunct Therapy; Other Treatments
  • 3) By Diagnosis: Blood Test; Genetic Test; Parenteral Test; Other Diagnosis
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Subsegment:
  • 1) By Type 1: Classic Fabry Disease; Later-Onset Fabry Disease
  • 2) By Type 2: Cardiovascular-Focused Fabry Disease; Renal-Focused Fabry Disease
  • 3) By Other Types: Variant Fabry Disease; X-linked Fabry Disease
  • Companies Mentioned: Sanofi S.A.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; JCR Pharmaceuticals Co. Ltd.; Sumitomo Pharma Co. Ltd
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fabry Disease Market Characteristics

3. Fabry Disease Market Trends And Strategies

4. Fabry Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Fabry Disease Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Fabry Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Fabry Disease Market Growth Rate Analysis
  • 5.4. Global Fabry Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Fabry Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Fabry Disease Total Addressable Market (TAM)

6. Fabry Disease Market Segmentation

  • 6.1. Global Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Type 1
  • Type 2
  • Other Types
  • 6.2. Global Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Enzyme Replacement Therapy
  • Oral Therapy
  • Adjunct Therapy
  • Other Treatments
  • 6.3. Global Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Blood Test
  • Genetic Test
  • Parenteral Test
  • Other Diagnosis
  • 6.4. Global Fabry Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Fabry Disease Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users
  • 6.6. Global Fabry Disease Market, Sub-Segmentation Of Type 1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Classic Fabry Disease
  • Later-Onset Fabry Disease
  • 6.7. Global Fabry Disease Market, Sub-Segmentation Of Type 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cardiovascular-Focused Fabry Disease
  • Renal-Focused Fabry Disease
  • 6.8. Global Fabry Disease Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Variant Fabry Disease
  • X-linked Fabry Disease

7. Fabry Disease Market Regional And Country Analysis

  • 7.1. Global Fabry Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Fabry Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fabry Disease Market

  • 8.1. Asia-Pacific Fabry Disease Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fabry Disease Market

  • 9.1. China Fabry Disease Market Overview
  • 9.2. China Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fabry Disease Market

  • 10.1. India Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fabry Disease Market

  • 11.1. Japan Fabry Disease Market Overview
  • 11.2. Japan Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fabry Disease Market

  • 12.1. Australia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fabry Disease Market

  • 13.1. Indonesia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fabry Disease Market

  • 14.1. South Korea Fabry Disease Market Overview
  • 14.2. South Korea Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fabry Disease Market

  • 15.1. Western Europe Fabry Disease Market Overview
  • 15.2. Western Europe Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fabry Disease Market

  • 16.1. UK Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fabry Disease Market

  • 17.1. Germany Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fabry Disease Market

  • 18.1. France Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fabry Disease Market

  • 19.1. Italy Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fabry Disease Market

  • 20.1. Spain Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fabry Disease Market

  • 21.1. Eastern Europe Fabry Disease Market Overview
  • 21.2. Eastern Europe Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fabry Disease Market

  • 22.1. Russia Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fabry Disease Market

  • 23.1. North America Fabry Disease Market Overview
  • 23.2. North America Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fabry Disease Market

  • 24.1. USA Fabry Disease Market Overview
  • 24.2. USA Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fabry Disease Market

  • 25.1. Canada Fabry Disease Market Overview
  • 25.2. Canada Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fabry Disease Market

  • 26.1. South America Fabry Disease Market Overview
  • 26.2. South America Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fabry Disease Market

  • 27.1. Brazil Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fabry Disease Market

  • 28.1. Middle East Fabry Disease Market Overview
  • 28.2. Middle East Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fabry Disease Market

  • 29.1. Africa Fabry Disease Market Overview
  • 29.2. Africa Fabry Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Fabry Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Fabry Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fabry Disease Market Competitive Landscape And Company Profiles

  • 30.1. Fabry Disease Market Competitive Landscape
  • 30.2. Fabry Disease Market Company Profiles
    • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. JCR Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sumitomo Pharma Co. Ltd Overview, Products and Services, Strategy and Financial Analysis

31. Fabry Disease Market Other Major And Innovative Companies

  • 31.1. Chiesi Farmaceutici S.p.A.
  • 31.2. Amicus Therapeutics Inc.
  • 31.3. Idorsia Pharmaceuticals Ltd
  • 31.4. Sangamo Therapeutics Inc.
  • 31.5. uniQure N.V.
  • 31.6. Protalix BioTherapeutics Inc.
  • 31.7. Spur Therapeutics Inc.
  • 31.8. Exegenesis Bio Inc.
  • 31.9. ISU ABXIS Co. Ltd.
  • 31.10. Eleva GmbH
  • 31.11. AceLink Therapeutics Inc.
  • 31.12. 4D Molecular Therapeutics Inc.
  • 31.13. iBio Inc.
  • 31.14. Freeline Therapeutics Holdings plc
  • 31.15. Greenovation Biotech GmbH

32. Global Fabry Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fabry Disease Market

34. Recent Developments In The Fabry Disease Market

35. Fabry Disease Market High Potential Countries, Segments and Strategies

  • 35.1 Fabry Disease Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Fabry Disease Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Fabry Disease Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer